Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Simvastatin and sildenafil combine to attenuate pulmonary hypertension Source: Eur Respir J 2009; 34: 948-957 Year: 2009
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017